Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy

Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy

(2014) Denise Skrombolas et al.   Expert Review of Clinical Immunology

IL-2 therapy in type 1 diabetes: “Trials” and tribulations

(2013) S. Alice Long et al.   CLINICAL IMMUNOLOGY

Limitations of IL-2 and Rapamycin in Immunotherapy of Type 1 Diabetes

(2013) Audrey Baeyens et al.   DIABETES

Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy

(2013) Wei Liao et al.   IMMUNITY

Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages

(2013) Ari B. Molofsky et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Type 2 innate lymphoid cells control eosinophil homeostasis

(2013) Jesse C. Nussbaum et al.   NATURE

Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells

(2013) Ben Roediger et al.   NATURE IMMUNOLOGY

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial

(2013) Agnès Hartemann et al.   Lancet Diabetes & Endocrinology

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs  -Cell Function

(2012) S. A. Long et al.   DIABETES

The Transcription Factor GATA-3 Controls Cell Fate and Maintenance of Type 2 Innate Lymphoid Cells

(2012) Thomas Hoyler et al.   IMMUNITY

Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis

(2011) David Saadoun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

(2011) John Koreth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low-dose subcutaneous interleukin-2 in patients with minimal residual lymphoid neoplasm disease

(2010) E. González-Barca et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity

(2010) Daniel R. Neill et al.   NATURE

Systemically dispersed innate IL-13-expressing cells in type 2 immunity

(2010) A. E. Price et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In vivo expansion of T reg cells with IL-2–mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression

(2009) Kylie E. Webster et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Innate production of TH2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cells

(2009) Kazuyo Moro et al.   NATURE

Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune Destruction

(2008) Qizhi Tang et al.   IMMUNITY